---
document_datetime: 2025-09-29 16:09:55
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/yesafili-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: yesafili-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3004058
conversion_datetime: 2025-12-27 16:33:32.148112
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Yesafili

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|---------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB / EMA/VR/0000291049 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted | 13/08/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000280967   | 14/07/2025   | N/A   |
|-----------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted   |            |     |                                  |                                                                                                                                    |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000278069 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 26/06/2025 | N/A |                                  |                                                                                                                                    |
| Variation type IB / EMA/VR/0000275575 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                         | 23/06/2025 | N/A |                                  |                                                                                                                                    |
| Variation type II / EMA/VR/0000245097 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b                                                                                                                                                                                                                                                                                                                               | 05/06/2025 |     | SmPC, Annex II, Labelling and PL | The SmPC and Annex II (Additional risk minimisation measures) has been updated to reflect the new presentation pre-filled syringe. |

<div style=\"page-break-after: always\"></div>

| Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted  B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted  B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | complex manufacturing processes - Accepted B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.2 Sterile medicinal products and biological/ immunological medicinal products - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000265998 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data, following assessment of the same change for the reference product. The PL is updated accordingly. In addition, the MAH took the opportunity to add warnings for polysorbate into the SmPC and the PL in line with the EC Excipient Guideline. Furthermore, the MAH took the opportunity to introduce editorial changes to the PI for HR, HU and IS to align with the reference product PI. | 12/05/2025 | SmPC and PL | To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data, following assessment of the same change for the reference product. The PL is updated accordingly. In addition, the MAH took the opportunity to add warnings for polysorbate into the SmPC and the PL in line with the EC Excipient Guideline. |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000246009   | 13/03/2025   | SmPC and PL   |
|-----------------------------------------|--------------|---------------|